Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Fc fragment (Fragment crystallizable region) is the constant portion of an antibody produced by proteolytic cleavage, distinct from the antigen-binding Fab regions. It consists primarily of the C-terminal constant domains (CH2, CH3, sometimes CH4 for IgM/IgE) of the heavy chains. The Fc fragment is crucial for immune effector activity: it binds to Fc receptors expressed on various immune cells (including macrophages, NK cells, neutrophils), and to components of the complement system, mediating cell lysis, phagocytosis, degranulation, and clearance of opsonized targets. Fc glycosylation is critical for these functions. While not a standalone therapeutic target, engineering the Fc region is central to therapeutic antibody development, regulating their efficacy, serum half-life, and immune activation.
Mediates antibody-dependent cellular cytotoxicity (ADCC) via Fcγ receptor binding; Mediates antibody-dependent cellular phagocytosis (ADCP); Activates complement-dependent cytotoxicity (CDC) via complement protein binding; Modulates serum half-life via neonatal Fc receptor (FcRn) interaction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fragment crystallizable region of immunoglobulin (Fc fragment (or Fc region)).